Eisai

Eisai

Community score

+1.14 -55
Industry: Biotechnology & Pharmaceuticals
Listing country: Japan
Year added: 2018

Eisai, a company established in 1941, is headquartered in Tokyo, Japan, and operates primarily in the pharmaceutical industry with a focus on neurology and oncology. Its neurology segment is dedicated to addressing conditions like Alzheimer's and epilepsy, while oncology is centered on developing cancer treatments. The company has developed significant drugs and brands, including Aricept for Alzheimer's disease, Halaven for breast cancer treatment, Fycompa for epilepsy, and Lenvima, which is used for treating thyroid cancer and various other cancer types. With a presence in multiple countries around the world, Eisai's important markets comprise Japan, the United States, China, and various European countries. The company maintains a global network to ensure its products are distributed and available to patients internationally. (Powered by AI)

Show Company Information
You view a limited profile page without scores and metrics availability. Subscribing users get to see more advanced data, want to see it in action? Click on a company you are interested in: .
My impact scoreBeta
List View